Team and Partners
A Multidisciplinary Team with a Global Vision
VIVA In Vitro Diagnostics has a highly skilled team that combines scientific excellence, business execution and disruptive purpose.
Our management team, scientific team, partners and advisory board are committed to innovation in biomedical diagnostics and personalised medicine.
Management Team
Joaquín Gómez Moya
He holds an MBA and a Master’s degree in International Business Management. More than 30 years of experience in senior management, including the launch of bio- and nano-technological solutions in Europe and the US in the bio-health and DeepTech sectors.
“Our goal is not to follow trends, but to create them: to turn science into solutions that redefine clinical standards”.
Toni Vilaplana Vivancos
MBA from IESE and lawyer. More than 25 years as a senior manager in large companies, as well as team management, and with more than 10 years of experience as a consultant in M&A transactions and restructurings.
“In a hyper-competitive sector, the difference is in executing with agility without losing scientific rigour and with the patient in mind”.
Dr. Pablo Pelegrín Vivancos
Deputy Scientific Director of IMIB, Professor of Immunology at the University of Murcia. Responsible for seminal contributions in this field, with international recognition for his research on inflammasomes and immune response.
“Real translation requires impeccable science and the courage to question dogmas”.
Scientific and Technical Team
Experts transforming science into cutting-edge diagnostic solutions.
Our team combines technical depth, translational insight and regulatory rigour to develop tools that make a difference in clinical practice.
Dra. Verónica Cánovas
PhD in Biochemistry, Molecular Biology and Biomedicine from the Autonomous University of Barcelona. Experience leading biomedical research in institutions such as Vall d’Hebron. She has been responsible for national and European biotechnology projects.
Pablo González Polanco
MSc in Biomedical Engineering (Marquette University), with extensive 510(k) experience before the FDA. From Massachusetts General Hospital, where developed microfluidic systems, he also led Quality and Regulatory Affairs in the design of a diagnostic system for coagulopathies.
María del Carmen Baños
More than 10 years of experience in Molecular Biology and Microbiology laboratories at IMIB and at the Faculty of Life Sciences of the University of Manchester. Postgraduate in Cell Culture and Animal Experimentation, Master in Clinical Trials.
Rocio Baños Martínez
Rocio’s contribution as a biomedical clinical laboratory technician is part of our growth as a company, which leads us to incorporate young talent with a strong commitment to our mission.
Alicia Blázquez
Our Head of Administration brings us the experience of more than 25 years working for SMEs, high-growth companies and companies in the biotechnology sector, as well as the management of human resources departments, financial management and relations with the public administration.
Juan Carlos Milena
Expert in corporate communication for corporations, startups and open innovation ecosystems, he offers us the necessary connection with national and international media, as well as direct actions with our audiences.
Ecosystem for clinical validation
Strategic partnerships to bring laboratory innovation to hospital practice.
Validating solutions in real-world environments requires collaboration with the best. Our clinical network combines multidisciplinary expertise, certified infrastructures and access to critical populations.
Dr. Carlos García Palenciano
Clinical Management. Head of Anaesthesia and Resuscitation Department at Hospital Universitario Virgen de la Arrixaca (Murcia).
Dra. Piedad Martínez Gil
Specialist in the Anaesthesia and Resuscitation Department at Hospital Universitario Virgen de la Arrixaca (Murcia).
Dra. Mar Luque Fernández
Specialist in Intensive Care Medicine at Hospital Universitario Virgen de la Victoria de Málaga (Málaga).
Dr. Ángel Estella
Specialist in Intensive Care Medicine at the University Hospital of Jerez de la Frontera (Cádiz).
Dr. Salvador López Cárdenas
Specialist in infectious diseases at the University Hospital of Jerez de la Frontera (Cádiz).
Strategic Partnerships and Collaborations
Thanks to the collaboration of:
Strategic Partnerships and Collaborations
Our company is at the centre of an ecosystem of alliances where institutions and companies of the highest prestige converge. From patners to accelerate market access to strong institutional backing.
International Scientific Advisory Committee
Leading the revolution in inflammasome research with a global vision
Coordinated by Dr. Pablo Pelegrín, our committee brings together the brightest minds in translational immunology to guide our developments with cutting-edge scientific rigour.
Dr. Mihai Netea
Head of the Division of Experimental Medicine at the Department of Internal Medicine at Radboud UMC, and one of the most cited authors in immunology. Specialist in infectious diseases and innate immunity to pathogens.
Dr. Eduardo López Collazo
Deputy Scientific Director of Health Research at the Hospital Universitario de la Paz and academic at the Latin American Academy of Sciences. His research interests include sepsis, cancer, leukaemia, cystic fibrosis, HIV and COVID-19.
Dra. Rebecca Coll
Leader in the study of inflammasomes and their role in inflammatory diseases. She has led the biological characterisation of MCC950, an inhibitor of the NLRP3 inflammasome, with an impact on diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis and atherosclerosis.
More than €3m investment to fight sepsis
Thanks to the investors, family offices and institutions that have given us their support. Among them Rafael Crespo, who is part of our Board of Directors, together with Joaquín Gómez Moya and Toni Vilaplana. In our newly created Advisory Board, we have Enrique Riquelme and Guillermo Forner, together with Murcia Emprende. They have been joined by prestigious investors such as Antonio Ruiz Ballesta, Fran Rodríguez and Antonio Soria.
